ReviewMedical oncology (Northwood, London, England)2025
CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Is CXCR4 Theranostics in Oncologic, Cardiovascular, and Inflammatory Diseases Really Happening?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015-2025).Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CXCR4/CXCL12 signaling axis governs leukemic stem cell dynamics within the bone marrow niche, driving migration, survival, and therapy resistance. This review examines a CXCR4-directed theranostic strategy for acute leukemia using Pentixafor and Pentixather. Pentixafor enables non-invasive visualization of CXCR4 expression, while Pentixather delivers targeted radiotherapy to CXCR4-expressing leukemic cells. We analyze how disrupting CXCR4-mediated leukemic cell-niche interactions enhances treatment efficacy and improves clinical outcomes in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). By integrating imaging and therapy, this approach offers a novel strategy to overcome microenvironment-mediated chemoresistance in hematologic malignancies. It advances personalized medicine by stratifying patients for CXCR4-targeted therapy and preserves functional hematopoietic niches, ultimately improving patient care.
Indexed as
Identifiers
40754635What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.